Introduction
It has long been recognized that the development of invasive malignancy requires multiple genetic events, and modern technologies now suggest that tens, if not hundreds, of genes may be aberrantly expressed in malignant cells. 1, 2 In the last decade, studies on p53 replacement have dominated the literature and it remains the only tumour suppressor gene to be evaluated formally in clinical trials. Here, we review the progress that has been made in the past 2 years in the field of tumour suppressor gene therapy and the future prospects for utilizing pathways other than p53, including the well characterized, such as retinoblastoma (Rb) and PTEN (phosphatase, tensin homologue, deleted on chromosome 10), as well as those described more recently, such as melanoma differentiation associated gene-7 (mda-7) and opioid binding protein/cell adhesion molecule-like gene (OPCML).
Clinical trials of p53 gene replacement have had limited success
After the promise of the first clinical trial of p53 gene replacement in non-small-cell lung carcinoma in 1996,
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Prospects
The ability to induce growth arrest and apoptosis in vitro does not guarantee clinical success. Fuller understanding of downstream targets of p53 and Rb is necessary. Clinical trials of second-generation oncolytic viruses targeting Rb pathway will be eagerly awaited Combinations of tumour suppressor genes may offer new greater therapeutic potential New tumour suppressor genes will be discovered those published in the past 2 years [3] [4] [5] [6] [7] have been somewhat disappointing. In a neoadjuvant bladder carcinoma trial 5 , 12 patients received either intratumoral or intravesical injections of an adenovirus-encoding wild-type p53 (Ad p53) 3 days prior to radical cystectomy. Interestingly, transfection efficiency was much greater following intravesical administration and, overall, 7/11 (64%) evaluable patients (including 7/9 of the intravesical cohort) had evidence of transgene expression by vector-specific reverse-transcriptase PCR (RT-PCR), as well as some evidence of increased expression (both mRNA and protein) of p21
Waf1/Cip1 , a p53 target gene. By contrast, in patients with locally advanced bladder cancer treated with intravesical Ad p53 at comparable doses, 6 only 2/7 (29%) tumours demonstrated p53 transgene expression, with no detectable changes in the expression of either p21
Waf1/Cip1 or Bax. When comparing transgene expression in these two bladder cancer trials, it is possible that the larger instillation volume (120 ml) and the use of a transfection-enhancing agent in the neoadjuvant trial 5 contributed to the higher transfection rates.
In a phase I recurrent glioma trial, 12 patients received intratumoral Ad p53 at doses between 3 Â 10 10 to 3 Â 10 12 particles, followed by tumour resection, at which time more Ad p53 was injected into the tumour bed. 7 Before Ad p53 injection, only one of eight assessed tumours was p53 positive (by immunohistochemistry), while 10/12 showed nuclear p53 staining after injection and 7/8 showed positive staining for p21
Waf1/Cip1 . However, the zone of transfected cells extended no more than 8 mm from the injection site and the median overall survival for the whole cohort was only 43 weeks.
In non-small-cell lung cancer, intratumoral injection of 7.5 Â 10 12 particles of Ad p53 every 21 or 28 days produced transgene expression in 17/25 (68%) tumours. Patients also received chemotherapy (either carboplatin and paclitaxel or cisplatin and vinorelbine), but the frequency of overall tumour response was the same in Ad p53-injected lesions and noninjected lesions (52 versus 48%, respectively). However, there was a suggestion that the Ad p53-treated lesions reduced in size by a greater amount than the noninjected controls.
Ovarian cancer is traditionally thought to be an appealing target for clinical gene therapy because the disease tends to remain localized within the abdominal cavity, so that intraperitoneal vector delivery is a rational strategy. The extensive experience of p53 gene therapy in this disease culminated in a randomized phase III trial in which women with p53-null or p53 mutant tumours were randomized to chemotherapy alone or chemotherapy plus intraperitoneal Ad p53 following optimum debulking primary surgery. However, the first interim analysis indicated that not only did Ad p53 fail to improve effectiveness but was also associated with increased toxicity. As a result, the study has been abandoned (reported in Zeimet and Marth 8 ).
Despite the limited clinical efficacy, some positive factors have emerged from these trials. Firstly, it is noticeable that the trials have been designed with credible scientific as well as clinical end points. Secondly, except for the experience in the ovarian phase III trial, of which few details are available, treatment has largely been well tolerated with minimal toxicity. However, one must address why the trials were relatively unsuccessful and two broad possibilities emerge. Firstly, there remains the perennial problem of optimizing gene transfer. Improving gene transfer in the clinical setting with delivery of vectors to tumours disseminated throughout the body is a huge problem and lies outside the scope of this review. Secondly, there remains the possibility that p53 is the 'wrong' transgene. Although p53 mutations are found in many malignancies and defective p53 function may be causally linked to chemotherapy resistance, 9 many aspects of p53 biology remain unanswered, especially what determines whether cells undergo apoptosis or cell cycle arrest in response to p53 activation. 10 There is some evidence that low-level p53 expression, such as is likely to result from adenoviral gene transfer, causes cell cycle arrest rather than cell death. Also, the proapoptotic function of p53 depends upon transactivation of genes such as Bax, Apaf-1, Fas and PTEN, whose own expression or activity may be abnormal in tumour cells. 11 It is known that mutant p53 can act in a dominant-negative manner in p53 tetramers, 12 which could negate the effect of ectopically expressed wild-type protein. Finally, there is evidence that polymorphisms of the p53 gene (especially codon 72 -arginine versus proline) can determine the responsiveness of tumours to chemo-and radiotherapy by influencing inhibition of p73. 13 Only once all these issues have been addressed is there likely to be any advance in the field of p53 gene replacement.
Replicating adenoviral vectors targeting abnormal p53 function have also had limited success in clinical trials
The adenovirus E1B 55 kDa protein suppresses p53 function in infected cells and E1B 55K-deleted adenoviral vectors may be able to replicate within and cause cytolysis of tumours with defective p53 function. In the past 2 years, six separate phase I/II trials of such a virus (variously known as dl1520, Onyx-015 and CI-1042) have been published, in a range of tumour types, including colorectal, 14,15 ovarian 16 and pancreatic carcinomas, 17, 18 and in patients with liver metastases from gastrointestinal malignancies. 19 A total of 93 patients received doses of up to 2 Â 10 12 viral particles per injection with no objective clinical responses seen in any patient treated with dl1520 as a single agent. However, in combination with chemotherapy, some responses were seen; with 5-FU, eight patients with colorectal liver metastases demonstrated either partial or minor responses, at least five of whom had previously been refractory to 5-FU. 14, 19 In primary pancreatic carcinoma, two patients had partial responses in combination with gemcitabine. 17 One complexity in analysing these results is that it is now apparent that cellular p53 status is not the only determinant of the replication of this virus. 20 There have been many reports of replication within cells that are p53 wild type and there is contradictory evidence on the possible importance of the mdm-2/hdm-2 inhibitor p14
Arf . 21, 22 Similarly, E1B 55K almost certainly has functions in addition to p53 suppression, including modulating viral and cellular mRNA nuclear transport and stimulating late viral mRNA translation. Given this, the results of the trials and the uncertainties over p53
Cancer gene therapy using tumour suppressor genes IA McNeish et al replacement, it seems unlikely that any further significant progress will be made with dl1520.
Targeting the Rb pathway: Rb mutants may be more potent tumour suppressors than wild-type Rb
Rb is the paradigmatic tumour suppressor gene, originally postulated in 1971. It is the target for transforming viral proteins such as HPV E7 and adenovirus E1A, inactivation of the Rb and p53 genes alone can induce malignancy in mouse models 23 and abnormalities in the Rb pathway and the G1/S checkpoint probably exist in all malignancies. 24 The pathway has many components that are potential targets for therapy (see Figure 1) . Upon growth stimulation, cyclin D expression increases and it forms complexes with cyclin-dependent kinase 4 (cdk4) or cdk6 and these complexes sequester the cdk inhibitor p27
Kip1 from cyclin E/cdk2. The cyclin D/cdk4 and cyclin E/cdk2 complexes are now able to phosphorylate Rb and this phosphorylated form of Rb can no longer bind the E2F family of transcription factors, freeing E2F to transactivate the genes necessary for S-phase entry. The activity of cyclin D/cdk is also controlled by the INK4 family of inhibitors, of which p16
INK4A is perhaps the best known.
Rather surprisingly, there have been many fewer studies on replacement of Rb family members than p53. Early reports suggested that the ability of Rb expression alone to inhibit tumour cell growth is variable and Rb expression may, paradoxically, inhibit p53-induced apoptosis. 25 94 , in addition to generating caspase-mediated apoptosis, appeared to induce cell cycle blockade at G2/ M (rather than G1) and also rapid telomere erosion with ensuing chromosomal instability. Although it had previously been reported that full-length Rb could inhibit telomerase, the cell cycle findings are novel and as yet unexplained.
Another 28 Taken together, these reports suggest that Rb mutants and splice variants may be more potent tumour suppressors than Rb. Data on the potential of the other two members of the Rb family, p107 and p130, in gene therapy are very limited, but retrovirus-mediated transfer of the p130 gene can suppress the growth of lung carcinoma cells in vitro and in vivo.
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New oncolytic adenoviruses also target the Rb pathway Following on from dl1520, a second generation of selectively replicating adenoviral vectors has now been developed. The viruses nearest to clinical trial specifically target Rb function. The adenoviral E1A protein contains two conserved regions, CR-1 (amino acids and CR-2 (amino acids 120-127), the latter critical for binding to and inactivating Rb and whose deletion prevents formation of E1A/Rb complexes. Two similar mutants have been described recently; dl922/947 is deleted in amino acids 122-129, 30 while D24 is deleted in amino acids 121-128. 31 Both have been assessed in in vitro and in vivo models of cancer and dl922/947 is capable of replicating with much greater efficiency within a panel of tumour cell lines than dl1520, with minimal S-phase induction in quiescent nonimmortalized cells. 30 Most recently, D24 has been modified further to include a RGD-4C peptide into the adenoviral fibre, which permits infection of cells independent of the normal coxsackie adenovirus receptor that is frequently expressed at very low levels on tumour cells.
32 D24-RGD is capable of lysing ovarian carcinoma and glioma cells in vitro, as well as extending the survival of mice-bearing xenografts of both tumour types. 32, 33 Of note, D24-RGD appeared to have a significantly greater cytopathic effect than D24 and its replication on normal human astrocytes was at least 3 log scales lower than a wild-type adenovirus. 33 Clinical trials of both D24-RGD and dl922/947 are imminent. Further adenoviral mutants also explore targeting of the Rb pathway. Ar6pAE2fF 34 and Onyx-411 35 both have an E2F promoter in place of the adenoviral E1A promoter. In addition, Onyx-411 has a second E2F promoter to drive the expression of the E4 region and is also deleted in the E1A-CR-2 region, like dl922/947. The rationale behind these modifications is that the E2F promoter is selectively activated in the presence of a defective Rb pathway and E4 gene products, especially E4 orf4/6, cooperate with E1A and E1B proteins to create a cellular environment that permits efficient expression of viral genes and thus productive viral infection. 36 Both Ar6pAE2fF and Onyx-411 demonstrate tumour-specific replication with minimal effect upon normal cells, including proliferating epithelial cells, and both were more potent and tumour selective than dl1520.
INK4/ARF locus provides two potential targets for gene therapy
The INK4/ARF locus on chromosome 9 encodes two separate tumour suppressor genes from alternative reading frames, p16 INK4A 38 In all cell lines, p16
INK4A appears as a more efficient inducer of growth arrest, but not apoptosis, than p53. In vivo, however, adenoviral p16
INK4A (Ad p16) produces statistically greater survival in p16
INK4A -and p53-null or wild-type models than Ad p53 alone or even Ad p16 and Ad p53 combined. Clearly, as has been mentioned above, the limited efficacy of Ad p53 could result from abnormalities in downstream effectors of p53-mediated apoptosis. However, the same may be true of pathways downstream of p16
INK4A . Therefore, it remains possible that p16
INK4A has additional functions, of which downregulation of vascular endothelial growth factor (VEGF) is one possibility. Other groups have recently demonstrated the efficacy of adenoviral p16
INK4A delivery in lymphoma 39 and glioma 40 models, but one note of caution is necessary. There is evidence that ectopic overexpression of p16 INK4A can produce resistance to some chemotherapy drugs, possibly by inducing G1 cell cycle arrest, as many chemotherapy drugs are at their most effect in S phase. 41 In the past 2 years, more interest has focused on p14
Arf . Several reports have demonstrated that adenoviral delivery of the p14
Arf gene is capable of inducing cell cycle arrest and apoptosis in a wide variety of tumour models [42] [43] [44] [45] [46] [47] and can sensitize cells to chemotherapy. 48 Initial reports suggested that intact p53 pathways were required for p14 Arf -mediated cytotoxicity [47] [48] [49] and that cotransfection with wild-type p53 could enhance the p14
Arf effect. 46 It now appears that p14 Arf is capable of affecting proteins other than p53, such as E2F-1,
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51 and topoisomerase I. 52 Cluster analysis of gene expression patterns in mouse embryo fibroblasts indicates that p19 ARF induces expression of both p53-dependent and -independent genes, the latter including members of the B-cell translocation family (Btg/Tob) that can inhibit proliferation in cells regardless of p53 status. 43 
Recently, p14
Arf has shown itself capable of inducing apoptosis in p53-and Bax-null DU145 prostate carcinoma cells. 42 In p53-null H358 lung carcinoma cells, p14
Arf induces arrest in G2 phase, followed by apoptosis. This G2 arrest correlates with inhibition of CDC2, inactivation of CDC25C and induction of p21 Waf1 . Of note, p14 Arf is capable of inducing tumour regression in H358 xenografts. 53 One possible explanation for the discrepancy between these results and earlier studies that suggested p53 was an absolute requirement for p14
Arf -mediated cell death is timing. 49 In p53-null cells, it takes up to 6 days for G2 arrest to take place, in contrast to only 24-48 h in p53-positive cells. 53 PTEN expression alters metastatic potential and reduces neovascularization PTEN, also known as MMAC1 and TEP-1, is a phosphatase whose importance as a tumour suppressor gene is being increasingly recognized. Although PTEN can dephosphorylate proteins such as focal adhesion kinase, its primary function is to degrade the products of phosphatidylinositol 3 0 -kinase (PI-3kinase) by dephosphorylating phosphatidylinositol 3,4,5-trisphosphate and phosphatidylinositol 3,4,-bisphosphate at the 3 0 position. One of the main downstream targets of the PI-3kinase pathway is the kinase Akt, also known as PKB (protein kinase B), which, in turn, can activate a wide range of signals that lead to cell proliferation and decreased apoptosis (see Figure 2) . Thus, the loss of PTEN activity, which is seen in up to 40% of all malignancies, 54, 55 can have diverse effects on cell growth and differentiation.
In the past 2 years, there have been a number of studies investigating PTEN gene replacement, many of which have focused on prostate cancer. In PTEN-null prostate cancer, expression of PTEN causes a decrease in Bcl-2 expression and sensitizes cells to doxorubicin and vincristine chemotherapy, 56 and also sensitizes cells to death receptor-mediated apoptosis that could be overcome with Bcl-2 overexpression. 57 In another prostate model, adenoviral PTEN (Ad PTEN) delivery to PC3 cells in vitro leads to G1 arrest, but not apoptosis. 58 Interestingly, when the PC3 cells are transfected with Ad PTEN and then implanted orthotopically into mice, there is no reduction in tumorigenicity, but a significant reduction in the development of lymph node metastases, implying that PTEN may not be a critical regulator Cancer gene therapy using tumour suppressor genes IA McNeish et al of tumour formation and growth, but a controller of dissemination. When Ad PTEN is injected directly into pre-existing prostate xenografts, there is no tumour regression, which further underlines this point. By contrast, injection of Ad PTEN into bladder xenografts produced demonstrable tumour regression and induction of apoptosis, but only in PTEN-null UM-UC-3 tumours. In tumours that are PTEN wild type, Ad PTEN injection produced only transient growth inhibition. 59 Alongside reduction in phosphorylated Akt expression, another observation from the UM-UC-3 tumours is a reduction in VEGF expression both in vitro and in vivo, the latter accompanied by a reduction in tumour vessel formation. VEGF is known to be an Akt/ PTEN target, 60 and neovascularization is a marker of transformation from low-to high-grade gliomas in humans with PTEN mutations seen almost exclusively in high-grade tumours. Further indication of the potential of PTEN to influence angiogenesis in glioma is shown with U87MG xenografts in mice. In the presence of PTEN expression, in vivo growth is reduced, with marked reduction in angiogenic activity. 61 Even in the presence of proangiogenic signals such as constitutive EGFR activation and/or p53 inactivation, Ad PTEN delivery to glioma xenografts in mice produces a marked reduction in tumour vascularity. 62 Therefore, there may be a differential role for PTEN in different tumour types, reducing invasion and metastatic potential in some models and inhibiting tumour vascularization in others.
Multiple new tumour suppressor genes offer new therapeutic possibilities, especially mda-7 and OPCML Mda-7 (also known as IL-24) is a member of the IL-10 family of cytokines and was first described as a potential tumour suppressor gene, when shown to be expressed on differentiated melanocytes but not melanoma cells. Subsequently, it was shown that adenoviral delivery of the mda-7 gene (Ad mda-7) is able to induce apoptosis in malignant cells but not normal epithelial cells in both melanoma 63 and NSCLC. 64 Work in the past 2 years has extended knowledge on this gene. Expression is downregulated in a wide variety of malignancies, 65 while restoration of expression via Ad mda-7 can also induce growth arrest in vivo. 66 The mechanisms via which mda-7 induces growth arrest and apoptosis are complex. It appears to upregulate the expression of TRAIL and its receptors DR4/5, which could sensitize tumour cells to death receptor-mediated apoptosis. 66 There is also evidence that mda-7 can increase the expression of the RNA-dependent protein kinase PKR in some NSCLC cells. 67 The normal role of PKR is to limit viral infection by inhibiting protein synthesis and hence block viral protein production, but it may also function as a regulator of tumorigenesis. Recently, microarray analysis suggests that Ad mda-7 transfection can alter expression of members of both the b-catenin and PI3kinase signalling pathways in some breast and NSCLC cell lines. 68 Curiously, this analysis was performed on the same NSCLC line (H1299) as had been studied previously, 67 but PKR was not one of the genes whose expression was upregulated. Finally, several reports suggest that mda-7 may have a role in angiogenesis. Ad mda-7 is able to inhibit endothelial cell differentiation and reduce tumour vascularity in human lung cancer xenografts in mice, 66 and purified mda-7 protein is capable of inhibiting endothelial cell differentiation and migration more effectively than endostatin. 69 Finally, another potential tumour suppressor gene has been identified in ovarian cancer that may have therapeutic potential. OPCML is a member of the family of Ig domain-containing glycosylphosphatidylinositolanchored cell adhesion molecules and its expression is completely absent in over 80% of ovarian carcinomas, including both established cell lines and primary tumours. 70 Interestingly, the downregulation appears due mainly to CpG island methylation, and restoration of OPCML expression was able to impair ovarian carcinoma cell growth both in vitro and in vivo. 70 Clearly, more work will be required to evaluate the pathways via which OPCML functions in ovarian carcinoma.
Conclusions and prospects
Although targeting tumour suppressor gene pathways is an attractive and logical strategy for cancer gene therapy, results from clinical trials have not mirrored the preclinical studies. Clearly, the ability to induce cell cycle arrest and apoptosis in vitro or growth arrest in mouse xenografts does not guarantee responses in clinical trials. Several specific hurdles must be overcome if such therapies are to become routine. Firstly, a greater understanding of the biology of the ubiquitous p53 and Rb tumour suppressor genes pathways is vital, especially an understanding of their own downstream targets and how these may be altered in malignancy. Secondly, other pathways need to be thoroughly evaluated, especially those that appear to be tumour-type specific. 0 -phosphoinositide-dependent kinase 1 (PDK1) and PDK2-mediated phosphorylation at positions T308 and S473. Activated Akt can then modulate multiple cellular pathways, leading to the inhibition of apoptosis and stimulation of cell growth. PTEN has intrinsic lipid phosphatase activity that removes the phosphate moeity from the 3 0 position of PIP 3 and PI(3,4)P 2 , and thus counters the antiapoptotic and growth stimulatory activities of PI3kinase and Akt.
Cancer gene therapy using tumour suppressor genes IA McNeish et al Surprisingly, little gene therapy work has been published on restoring well-known tumour suppressor genes such as BRCA1 in breast cancer and APC in colon cancer. The novel genes, OPCML and mda-7, may offer new diseasespecific pathways to target in ovarian and melanoma/ lung carcinoma, respectively. Thirdly, restoring tumour suppressor gene function alone may be insufficient and combination treatments, either with multiple genes (eg one disease-specific and one ubiquitous gene) or a tumour suppressor gene with an apoptosis inducer such as chemotherapy or activated caspases, may be required. However, one thing is certain: extending our knowledge of tumour suppressor genes and their normal roles must ultimately lead to improved therapies for all malignancies.
